10/18/2024

Janusmed sex and gender

Janusmed sex and gender – hydrocortisone

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Hydrocortisone – topical

Hydrocortisone – topical

Class : B

  1. Nyberg F, Osika I, Evengård B. "The Laundry Bag Project"--unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol. 2008;47:144-9.
  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]
A A
A A

Hydrocortisone – systemic use

Hydrocortisone – systemic use

Class : A

  1. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-87.
  2. Donnan PT, Libby G, Boyter AC, Thompson P. The population risk of fractures attributable to oral corticosteroids. Pharmacoepidemiol Drug Saf. 2005;14:177-86.
  3. Hansen KE, Kleker B, Safdar N, Bartels CM. A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children. Semin Arthritis Rheum. 2014;44:47-54.
  4. Solu-Cortef (hydrocortisone). Summary of Product Characteristics. Medical Products Agency Sweden; 2015.
  5. Charmandari E, Hindmarsh PC, Johnston A, Brook CG. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. J Clin Endocrinol Metab. 2001;86:2701-8.
  6. Deslauriers JR, Lenz AM, Root AW, Diamond FB, Bercu BB. Gender related differences in glucocorticoid therapy and growth outcomes among pubertal children with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH). J Pediatr Endocrinol Metab. 2012;25:977-81.
  7. Hochberg Z, Schechter J, Benderly A, Leiberman E, Rosler A. Growth and pubertal development in patients with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency. Am J Dis Child. 1985;139:771-6.
  8. Belgorosky A, Chahin S, Rivarola MA. Elevation of serum luteinizing hormone levels during hydrocortisone treatment in infant girls with 21-hydroxylase deficiency. Acta Paediatr. 1996;85:1172-5.
  9. Werumeus Buning J, Kootstra-Ros JE, Brummelman P, van den Berg G, van der Klauw M, Wolffenbuttel BH et al. Higher hydrocortisone dose increases bilirubin in hypopituitary patients- results from an RCT. Eur J Clin Invest. 2016;46:475-80.
  10. Yu TJ, Liu YC, Yu CC, Tseng JC, Hua CC, Wu HP. Comparing hydrocortisone and methylprednisolone in patients with septic shock. Adv Ther. 2009;26:728-35.
  11. Karemaker R, Heijnen CJ, Veen S, Baerts W, Samsom J, Visser GH et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res. 2006;60:745-50.
  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-09.]